Literature DB >> 9286235

Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis.

A J Czaja1, F Cassani, M Cataleta, P Valentini, F B Bianchi.   

Abstract

To determine the significance of antinuclear antibodies and their patterns of indirect immunofluorescence in type 1 autoimmune hepatitis, sera from 99 patients were evaluated. Patients with antinuclear antibodies had a lower frequency of liver transplantation (6% vs 22%, P = 0.04) than seronegative patients. They were also more commonly HLA-DR4-positive than seronegative patients (56% vs 30%, P = 0.05) and normal subjects (56% vs 30%, P = 0.004). The 42 patients with antinuclear antibodies and a diffuse pattern of indirect immunofluorescence had higher serum titers of ANA (serum titers > or = 1:500, 71% vs 14%, P < 0.0001) and SMA (serum titers > or = 1:500, 69% vs 27%, P = 0.003) than the 22 patients with antinuclear antibodies and a speckled pattern. These patients, however, were otherwise not distinguished by clinical features and treatment response. Patients with a speckled pattern had A1-B8-DR3 more frequently than patients with a diffuse pattern (65% vs 23%, P = 0.005) and normal subjects (65% vs 13%, P < 0.0001), but they had no other salient features. We conclude that patients with antinuclear antibodies have a better long-term prognosis than seronegative patients, and they have HLA-DR4 more commonly. The patterns of indirect immunofluorescence associated with ANA positivity have no practical clinical implications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286235     DOI: 10.1023/a:1018809431189

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

Review 1.  Autoantibodies.

Authors:  A J Czaja
Journal:  Baillieres Clin Gastroenterol       Date:  1995-12

Review 2.  Clinical significance and interpretation of antinuclear antibodies.

Authors:  R H White; D L Robbins
Journal:  West J Med       Date:  1987-08

3.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

4.  Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.

Authors:  A J Czaja; M D Strettell; L J Thomson; P J Santrach; S B Moore; P T Donaldson; R Williams
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

5.  Immunomorphological characterisation of antinuclear antibodies in chronic liver disease.

Authors:  F Cassani; F B Bianchi; M Lenzi; U Volta; E Pisi
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

6.  Significance of HLA DR4 in type 1 autoimmune hepatitis.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

7.  Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.

Authors:  A J Czaja; M P Manns; H A Homburger
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

8.  Validation of scoring system for diagnosis of autoimmune hepatitis.

Authors:  A Czaja; H A Carpenter
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

Review 9.  Recently characterised autoantibodies and their clinical significance.

Authors:  A Sturgess
Journal:  Aust N Z J Med       Date:  1992-06

10.  Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis.

Authors:  D G Doherty; P T Donaldson; J A Underhill; J M Farrant; A Duthie; G Mieli-Vergani; I G McFarlane; P J Johnson; A L Eddleston; A P Mowat
Journal:  Hepatology       Date:  1994-03       Impact factor: 17.425

View more
  9 in total

1.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

2.  Genetic distinctions between autoimmune hepatitis in Italy and North America.

Authors:  Paolo Muratori; Albert-J Czaja; Luigi Muratori; Georgios Pappas; Silvana Maccariello; Fabio Cassani; Alessandro Granito; Rodolfo Ferrari; Vilma Mantovani; Marco Lenzi; Francesco-B Bianchi
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

3.  Performance parameters of the conventional serological markers for autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

4.  Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

5.  Hepatocellular carcinoma in autoimmune hepatitis.

Authors:  S Z Park; D M Nagorney; A J Czaja
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

6.  Frequency and significance of antibodies to chromatin in autoimmune hepatitis.

Authors:  Albert J Czaja; Zakera Shums; Walter L Binder; Stephen J Lewis; Vicki J Nelson; Gary L Norman
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

7.  Hepatocellular carcinoma in patients with autoimmune hepatitis.

Authors:  Andreas Teufel; Arndt Weinmann; Catherine Centner; Anja Piendl; Ansgar W Lohse; Peter R Galle; Stephan Kanzler
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

8.  Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.

Authors:  Kalliopi Zachou; Eirini Rigopoulou; George N Dalekos
Journal:  J Autoimmune Dis       Date:  2004-10-15

Review 9.  Update on Autoimmune Hepatitis.

Authors:  Rodrigo Liberal; Diego Vergani; Giorgina Mieli-Vergani
Journal:  J Clin Transl Hepatol       Date:  2015-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.